Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Psychopharmacol. 2007 Apr;22(3):121-8.

Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review.

Author information

1
Section of Psychiatry and Clinical Psychology, Department of Medicine and Public Health, University of Verona, Ospedale-Policlinico G. Rossi, Piazzale L. Scuro., Verona, Italy. cesario.bellantuono@univr.it

Erratum in

  • Hum Psychopharmacol. 2007 Aug;22(6):413.

Abstract

OBJECTIVE:

To review studies conducted to establish the risk of major congenital malformations in women exposed to serotonin reuptake inhibitors (SRIs) during the first trimester of pregnancy.

METHODS:

A literature search [corrected] was conducted within PsycINFO [corrected] EMBASE, MEDLINE and Cochrane databases from 1966 to October 2006, to identify studies assessing the risk of major malformations in infants whose mother was taking SRIs (SSRIs and SNRIs) during the first trimester of pregnancy.

RESULTS:

Fifteen studies were selected for the analysis: seven adopted a prospective cohort design and seven a retrospective design, of these one was a case-control study.

DATA SYNTHESIS AND CONCLUSIONS:

The reviewed studies suggest that exposure to fluoxetine, sertraline, citalopram and venlafaxine in early pregnancy is not associated with an increased risk of major congenital malformations. For paroxetine, recent data call for caution in prescribing such a drug in early pregnancy. For the other SRIs, the risk remains substantially undetermined, as data are so far scanty. Given this background, large prospective cohort studies are urgently needed to better assess the risk/benefit ratio of SRIs-treatment during pregnancy.

PMID:
17397101
DOI:
10.1002/hup.836
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center